Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Go back to Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 8.33 +0.48 (6.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.85 | 52 Week High | $7.49 | |||
| Open | $7.80 | 52 Week Low | $2.61 | |||
| Day High | $8.60 | P/E | N/A | |||
| Day Low | $7.60 | EPS | $-1.10 | |||
| Volume | 1,299,719 | |||||
| (NASDAQ: INKT) | Delayed: 12.25 +0.20 (1.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.05 | 52 Week High | $ | |||
| Open | $11.84 | 52 Week Low | $ | |||
| Day High | $12.69 | P/E | N/A | |||
| Day Low | $11.57 | EPS | $ | |||
| Volume | 8,030 | |||||
